🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Heading to the afternoon sessions at #AACR25? Don’t miss our poster presentations starting at 2 pm CT, featuring Dunja Urosev, Nicole Afacan, and Patricia Zwierzchowski, who will share new preclinical data on our antibody-drug conjugate and T cell engager programs. Stop by and

Today at #AACR25, Raffaele Colombo presents our collaboration poster with Discovery Life Sciences, titled "In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload (submitted with Discovery Life Sciences)! View the poster here:

It’s the final day of poster presentations at #AACR25 and we’re closing it out with a presentation showcasing new preclinical data on our novel trispecific T cell engager integrated with CD28 co-stimulation. Come by Section 40 and meet research leads Diana Canals, Desmond Lau,

In a recent issue of Drug Development & Delivery, Paul Moore, Raffaele Colombo, and Jamie Rich delve into the history of antibody-drug conjugate development and how recent advancements on novel camptothecin payloads can unlock new breakthroughs in biotherapeutics. Read the full

At Zymeworks, we know that innovation thrives in a culture of collaboration, curiosity, and continuous growth. As we participate in conferences like #AACR25, we’re not only inspired by groundbreaking discussions in oncology research but also driven by connections with passionate

And that's a wrap for #AACR25! Last week, our team gathered in Chicago for an insightful and connection-building experience amongst hundreds of the best and brightest in cancer research. We are grateful for the opportunity to attend and present the latest advancements in our ADC

Today, Paul Moore will be presenting and attending one-on-one meetings during the Bloom Burton & Co. Healthcare Investor Conference in Toronto. The annual convening brings together global investors who are interested in the latest developments in Canadian healthcare companies.

We’re happy to announce that Zymeworks is headed to #ATS2025! 🌟 Bringing together the #thoracic research and clinical care communities, the American Thoracic Society’s Annual Meeting offers an opportunity to engage and connect over exciting new research from our respiratory and

Applications are now open for our Fall 2025 co-op program! If you're a student passionate about science, technology, and making an impact in healthcare, this is your chance to gain hands-on experience for eight months with a team driving innovation in biotherapeutics. 📌

Zymeworks announces its Q1 2025 financial results. Join our senior management team for a webcast today at 4:30 PM ET as they walk through the highlights and key updates. Read the press release: ir.zymeworks.com/news-releases/…

Two Zymeworks researchers, one mission: engineering therapies that make a meaningful impact for patients. At #ATS2025, Alexey Berezhnoy and Blair Hardman will present new preclinical data on our IL-4Rα x IL-33 bispecific to treat respiratory inflammation. Learn more:

In a recent episode of Empowered Patient Podcast with Karen Jagoda, our Chief Scientific Officer Paul Moore shares how Zymeworks is pushing the boundaries of biotherapeutics with a clear focus: improving patient outcomes. Listen to the full episode: empoweredpatientradio.com/multispecific-…

We’re excited to share new preclinical data at #ATS2025 on our novel IL-4Rα x IL-33 bispecific antibody designed to address chronic obstructive pulmonary disease (COPD). This work reflects our continued commitment to expanding therapeutic options for patients with

Next month, our management team will be participating in meetings and presentations at the following investor conferences: June 4: Jefferies Global Healthcare Conference June 11: Goldman Sachs Global Healthcare Conference June 17: Citi European Healthcare Conference Learn more

We’re thrilled to be presenting continued progress across our oncology portfolio at upcoming medical conferences. Key highlights include: • Partner-led presentations showcasing the strength and versatility of our Azymetric™ platform • Phase 2 long-term outcomes and survival

This Memorial Day, we pause to honor and remember the brave individuals who gave their lives in service to their country. Their sacrifice is a powerful reminder of the freedoms we hold and the responsibility we share to uphold them. At Zymeworks, we are deeply grateful to those

Exciting News: We’re proud to share that our bispecific antibody has been approved in China for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) — a significant milestone for patients facing this

Today, our management team will be participating in a fireside chat at Jefferies Global Healthcare Conference, starting at 2:35 p.m. EST. Access the live webcast:​​ ir.zymeworks.com/events-and-pre… #Biotech #Conferences

#ASCO25 has come to a close — and it’s been an incredible showcase of collaboration, discovery, and momentum in oncology. We’re grateful to all who joined us — from those who attended our presentations to those who shared in meaningful conversations with our team. We’re leaving